Syntara Limited · ASX:SNT
Syntara — Earnings Presentation (October 2023)
11 slides from Syntara's earnings presentation, October 2023
Slide 1: Quarterly update
™ Quarterly update Gary Phillips, CEO October 2023
Slide 2: Forward looking statement
Forward looking statement This document contains involve known and unknown forward-looking statements, risks, uncertainties and other including statements factors, many of which are concerning Pharmaxis’ future beyond our control, and which financial position, plans, and may cause actual results to
Slide 3: Pharmaxis evolves to Syntara: Cost savings and clear focus energise clinical programs
Pharmaxis evolves to Syntara1: Cost savings and clear focus energise Syntara clinical programs The main factors impacting cash from separation Proforma Cash Expenses 2023 of the mannitol business unit are: 35,000 • Employee numbers dropping from ~70 to ~25 30,000 • Much reduced new lease for researc
Slide 4: Quarterly Shareholder Update - the launch of Syntara
Quarterly Shareholder Update - the launch of Syntara • Smaller and very focused Board under new leadership • A science platform that leads the world in its field and has been internationally acclaimed with three recent Nature publications • A strong pipeline of clinical stage assets with a lead prog
Slide 5: Phase 2a study cohort added to trial PXS-5505 in patients on a stable dose of JAK inhibitor
Phase 2a study cohort added to trial PXS-5505 in patients on a stable dose of JAK inhibitor Fastest route to meaningful data with no dose escalation and utilizing existing trial infrastructure Study Plan • 20 clinical trial sites scheduled to be open for Study recruitment by Design Treatment Endpoin
Slide 6: Strong interest in myelofibrosis assets from strategic acquirers
Strong interest in myelofibrosis assets from strategic Target / Acquiror / / / / / / Date of June-2023 July-2022 December-2020 November-2022 September-2020 January-2018 Announcement Combination of Drug Name Pacritinib Momelotinib Bomedemstat AVID200 Fedratinib Ruxolitinib & CK0804 Myelofibrosis & Le
Slide 7: Potential for five trials to deliver near term value
Potential for five trials to deliver near term value Pipeline creates multiple opportunities in high value markets Drug Upcoming Addressable Indication Phase Trial design Status Candidate Milestones market (US$) • Open label 12 month study (n=15) First 2H 2024: Myelofibrosis • MF patients receiving
Slide 8: News flow
News flow Recent and anticipated news flow Strong and growing pipeline with advancement in studies expected to provide value inflection points Q4 2023 H1 2024 H2 2024 • PXS-5505 phase 2a myelofibrosis • PXS-5505 phase 2a myelofibrosis • PXS-5505 phase 2a combination study (add on to JAK combination
Slide 9: Shareholders & Cash
Shareholders & Cash Financial Information 30 Sept 23 Institutional Ownership 30 Sept 23 ASX Code1 PXS BVF Partners LP 14% Karst Peak Capital Limited 12% Share price $0.033 D&A Income Limited 11% Liquidity (turnover last 12 months) 124m shares Platinum Investment Management 8% Limited Market Cap A$26
Slide 10: Q&A
Q&A 10
Slide 11: Gary Phillips
Gary Phillips Pharmaxis Ltd ABN 75 082 811 630 Chief Executive Officer gary.phillips@pharmaxis.com.au David McGarvey Chief Financial Officer david.mcgarvey@pharmaxis.com.au www.pharmaxis.com.au